These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond. Abbaszadeh S; Nosrati-Siahmazgi V; Musaie K; Rezaei S; Qahremani M; Xiao B; Santos HA; Shahbazi MA Adv Drug Deliv Rev; 2023 Sep; 200():115050. PubMed ID: 37549847 [TBL] [Abstract][Full Text] [Related]
45. Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy. Li J; Luo Y; Li B; Xia Y; Wang H; Fu C Front Bioeng Biotechnol; 2020; 8():612950. PubMed ID: 33330440 [TBL] [Abstract][Full Text] [Related]
46. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
47. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642 [TBL] [Abstract][Full Text] [Related]
48. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557 [TBL] [Abstract][Full Text] [Related]
49. Biomaterials-Mediated Engineering of the Immune System. Backlund C; Jalili-Firoozinezhad S; Kim B; Irvine DJ Annu Rev Immunol; 2023 Apr; 41():153-179. PubMed ID: 36696570 [TBL] [Abstract][Full Text] [Related]
50. Immunomodulatory metal-based biomaterials for cancer immunotherapy. Yuan K; Zhang C; Pan X; Hu B; Zhang J; Yang G J Control Release; 2024 Nov; 375():249-268. PubMed ID: 39260573 [TBL] [Abstract][Full Text] [Related]
51. [Basics of cancer immunotherapy]. Fujioka Y; Nishikawa H Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285 [TBL] [Abstract][Full Text] [Related]
52. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. Ruan S; Huang Y; He M; Gao H Adv Sci (Weinh); 2022 May; 9(16):e2200027. PubMed ID: 35343112 [TBL] [Abstract][Full Text] [Related]
53. Enhancing cancer immunotherapy with nanomedicine. Irvine DJ; Dane EL Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979 [TBL] [Abstract][Full Text] [Related]
54. Novel immunotherapies for hematologic malignancies. Nelson MH; Paulos CM Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273 [TBL] [Abstract][Full Text] [Related]
56. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. Desai N; Hasan U; K J; Mani R; Chauhan M; Basu SM; Giri J Acta Biomater; 2023 Apr; 161():1-36. PubMed ID: 36907233 [TBL] [Abstract][Full Text] [Related]
57. Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy. Yuan C; Liu Y; Wang T; Sun M; Chen X ACS Biomater Sci Eng; 2020 Sep; 6(9):4774-4798. PubMed ID: 33455212 [TBL] [Abstract][Full Text] [Related]
58. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535 [TBL] [Abstract][Full Text] [Related]
59. Cancer immunotherapies, their safety and toxicity. Alatrash G; Jakher H; Stafford PD; Mittendorf EA Expert Opin Drug Saf; 2013 Sep; 12(5):631-45. PubMed ID: 23668362 [TBL] [Abstract][Full Text] [Related]
60. Protein-Engineered Biomaterials for Cancer Theranostics. Liu X; Wang C; Liu Z Adv Healthc Mater; 2018 Oct; 7(20):e1800913. PubMed ID: 30260583 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]